BCYC Bicycle Therapeutics plc

10.91
-1.1  -9%
Previous Close 12.01
Open 12.95
Price To Book 1.87
Market Cap 195,296,975
Shares 17,900,731
Volume 15,227
Short Ratio
Av. Daily Volume 20,490

NewsSee all news

  1. Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

           Immediate onset of action - starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149.Prolonged

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 safety and tolerability data released July 1, 2019.
THR-149
Diabetic Macular Edema
Phase 1 initial data due 2H 2019. Phase 2 trial to also commence 2H 2019.
BT1718
Solid tumors

Latest News

  1. Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

           Immediate onset of action - starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149.Prolonged